COYA · Coya Therapeutics, Inc.
Coya Therapeutics Inc (COYA)
What's happening
- COYA is down 3.05% today, trading at $4.13. — Live quote
- Volume today (6,057) is well below its 3-month average of 174,320. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.28 actual vs. $-0.35 estimated (+19.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $139.2M | $88.7M | $91.2M | $97.4M | $109.5M |
| P/E | -6.31 | -3.90 | -4.67 | -4.79 | -5.68 |
| Price/Sales | 32.96 | 20.94 | 22.89 | 25.31 | 28.75 |
| Price/Book | 3.22 | 1.81 | 3.34 | 3.44 | 3.28 |
| EV/Revenue | 22.73 | 8.97 | 15.83 | 17.57 | 19.42 |
| ROE | -50.97% | -46.40% | -71.61% | -71.76% | -57.75% |
| ROA | -46.62% | -42.66% | -60.98% | -60.73% | -50.18% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 49.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -270.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -34.3%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on COYA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $243.7K | $251.1K | $3.6M | $163.6K | $257.9K | $0 | $3.4M | $126.8K |
| Operating income | -$7.0M | -$7.6M | -$2.4M | -$6.4M | -$7.7M | -$4.5M | -$3.2M | -$5.5M |
| Net income | -$6.6M | -$7.2M | -$2.1M | -$6.1M | -$7.3M | -$4.0M | -$2.9M | -$5.1M |
| EPS (diluted) | $-0.28 | $-0.32 | $-0.13 | $-0.36 | $-0.44 | $-0.26 | $-0.19 | $-0.35 |
| EPS (basic) | $-0.28 | $-0.32 | $-0.13 | $-0.36 | $-0.44 | $-0.26 | $-0.19 | $-0.35 |
| Operating margin | -$2.9K | -$3.0K | -$68 | -$3.9K | -$3.0K | — | -$94 | -$4.3K |
| Net margin | -$2.7K | -$2.9K | -$59 | -$3.7K | -$2.8K | — | -$84 | -$4.0K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $47.3M | $53.3M | $50.0M | $32.0M | $33.5M | $38.4M | $44.3M | $35.6M |
| Total liabilities | $4.0M | $4.3M | $6.9M | $4.8M | $5.1M | $5.0M | $4.8M | $3.5M |
| Stockholders' equity | $43.3M | $49.0M | $43.0M | $27.3M | $28.3M | $33.4M | $39.6M | $32.0M |
| Total current assets | $47.1M | $53.3M | $49.9M | $32.0M | $33.4M | $38.4M | $44.3M | $35.5M |
| Total current liabilities | $3.5M | $3.5M | $5.9M | $3.7M | $4.5M | $4.3M | $3.8M | $2.3M |
| Cash & equivalents | $43.2M | $50.7M | $46.8M | $28.1M | $29.8M | $35.5M | $38.3M | $31.1M |
| Property, plant & equipment | $5.6K | $8.4K | $11.2K | $18.1K | $24.9K | $31.7K | $38.6K | $45.4K |
| Other non-current assets | $244.7K | — | — | — | — | — | — | — |
| Accounts payable | $1.1M | $948.2K | $1.1M | $1.1M | $931.3K | $1.7M | $1.6M | $336.7K |
| Accrued liabilities | $1.2M | $1.4M | $3.6M | $1.6M | $2.8M | $1.8M | $1.4M | $1.4M |
| Deferred revenue (current) | $1.2M | $1.2M | $1.2M | $916.7K | $731.1K | $841.4K | $848.3K | $573.1K |
| Common stock & paid-in capital | $2.3K | $2.3K | $2.1K | $1.7K | $1.7K | $1.7K | $1.7K | $1.5K |
| Retained earnings | -$75.8M | -$69.2M | -$62.0M | -$56.3M | -$54.1M | -$48.0M | -$40.7M | -$37.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.4M | -$6.2M | -$1.0M | -$1.1M | -$5.8M | -$2.8M | -$2.4M | -$5.5M |
| Investing cash flow | -$1.7K | -$885.0K | -$648.6K | -$516.0K | — | — | $0 | $0 |
| Financing cash flow | -$166.1K | $11.0M | $20.3M | $19.1K | $0 | $19.1K | $9.7M | -$56.3K |
| Share-based compensation | $943.9K | $2.2M | $1.1M | $1.1M | $1.0M | $1.1M | $790.5K | $775.0K |
| Change in accounts payable | $58.7K | -$154.7K | -$50.6K | $180.4K | -$758.7K | $101.9K | $1.3M | -$1.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M | -$4.9M |
| EPS (diluted) | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| EPS (basic) | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
| Operating margin | -$284 | -$485 | -$132 | — | — |
| Net margin | -$267 | -$419 | -$133 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M |
| Stockholders' equity | $43.0M | $39.6M | $35.6M | -$8.4M | $3.6M |
| Total current assets | $49.9M | $44.3M | $41.2M | $7.2M | $4.6M |
| Total current liabilities | $5.9M | $3.8M | $5.1M | $3.8M | $1.1M |
| Cash & equivalents | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M |
| Property, plant & equipment | $11.2K | $38.6K | $65.9K | $93.3K | $120.7K |
| Accounts payable | $1.1M | $1.6M | $1.2M | $1.8M | $857.6K |
| Accrued liabilities | $3.6M | $1.4M | $3.0M | $2.0M | $290.8K |
| Deferred revenue (current) | $1.2M | $848.3K | $923.1K | — | — |
| Common stock & paid-in capital | $2.1K | $1.7K | $1.4K | $259 | $259 |
| Retained earnings | -$62.0M | -$40.7M | -$25.9M | -$17.9M | -$5.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M |
| Investing cash flow | -$1.2M | -$25.0K | -$543.2K | -$525.0K | -$136.8K |
| Financing cash flow | $20.4M | $16.0M | $38.4M | $9.4M | -$340.6K |
| Share-based compensation | $4.3M | $2.7M | $872.2K | $207.3K | $233.2K |
| Change in accounts payable | -$527.0K | $477.4K | $298.8K | $845.3K | $665.2K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding COYA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-08-18 to 2025-08-18
Recent transactions
- Most recent: GOLDSTEIN DOV A MD (Director) — Option exercise of 17,557 shares on 2025-08-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| GOLDSTEIN DOV A MD | Director | Option exercise | 2025-08-18 | 17,557 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-08-18 | GOLDSTEIN DOV A MD | Director | Option exercise | 17,557 | $1.09 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-04-09 | 4 | 2026-04-09 | View on SEC.gov → |
| 2026-04-02 | 8-K | 2026-03-29 | View on SEC.gov → |
| 2026-03-16 | 10-K | 2025-12-31 | View on SEC.gov → |
Recent news
Headlines about COYA (Coya Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Coya Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (COYA)
Traders Union · 2026-10-17 -
COYA261016P00007500 Interactive Stock Chart | COYA Oct 2026 7.500 put Stock
Yahoo! Finance Canada · 2026-10-15 -
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Yahoo · 2026-10-14 -
Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis
Benzinga · 2026-10-14 -
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Yahoo · 2026-10-13 -
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Yahoo Finance · 2026-10-05 -
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Yahoo Finance · 2026-09-15 -
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Yahoo Finance · 2026-09-08
No headlines in this category right now — try “All”.